Home › Funds › Siren, L.L.C. › DNLI
Siren, L.L.C. position in DNLI
Denali Therapeutics Inc. · Health Care
Siren, L.L.C. reported holding 1,396,513 shares of DNLI (Denali Therapeutics Inc.) in its Q3 2026 13F filing — a position valued at US$28.9M, representing 0.69% of its reported portfolio and ranking #35 among its reported holdings. Siren, L.L.C. has disclosed DNLI holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Siren, L.L.C.'s DNLI position evolved
Siren, L.L.C. first disclosed a stake in DNLI in Q3 2024 at 834,028 shares (US$24.3M). The position peaked in Q2 2026 at 1,396,513 shares, worth US$35.9M. Across 9 filings, Siren, L.L.C. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 1,396,513 shares valued at US$28.9M. Notable position changes include a 70% increase in Q4 2025 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 834.03K | $24.30M | New |
| Q4 2024 | 834.03K | $17.00M | Hold |
| Q1 2025 | 821.51K | $11.17M | Reduce |
| Q2 2025 | 821.51K | $11.49M | Hold |
| Q3 2025 | 821.51K | $11.93M | Hold |
| Q4 2025 | 1.40M | $23.06M | Add |
| Q1 2026 | 1.40M | $26.81M | Hold |
| Q2 2026 | 1.40M | $35.92M | Hold |
| Q3 2026 | 1.40M | $28.87M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNLI and 13F data
DNLI (Denali Therapeutics Inc.) is a Health Care company. 43 other funds we track also report a position in DNLI — the largest reported positions include Temasek Holdings (US$180.4M), Temasek Holdings (Private) Ltd (US$180.4M), BAKER BROS. ADVISORS LP (US$96.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNLI
- Temasek Holdings 7.01M sh · $180.37M · Q2 2026
- Temasek Holdings (Private) Ltd 7.01M sh · $180.37M · Q2 2026
- BAKER BROS. ADVISORS LP 3.73M sh · $96.05M · Q2 2026
- Casdin Capital 2.04M sh · $52.60M · Q2 2026
- Crestline Management, L.P. 1.91M sh · $49.14M · Q2 2026
- Foresite Capital Management VI LLC 1.40M sh · $35.92M · Q2 2026
- ADAR1 Capital Management, LLC 1.03M sh · $26.47M · Q2 2026
More on Siren, L.L.C.
FAQ
How long has Siren, L.L.C. held DNLI?
Siren, L.L.C. has disclosed DNLI holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Siren, L.L.C.'s current position in DNLI?
As of Q3 2026, Siren, L.L.C. holds 1.40M shares of DNLI (Denali Therapeutics Inc.), valued at $28.87M, representing 0.69% of its reported portfolio and ranking #35.
Has Siren, L.L.C. been buying or selling DNLI?
In the latest 13F filing (Q3 2026), Siren, L.L.C. held unchanged its position in DNLI. The position peaked in Q2 2026 at 1.40M shares.
Which other funds hold DNLI?
Other major institutional holders of DNLI include Temasek Holdings, Temasek Holdings (Private) Ltd, BAKER BROS. ADVISORS LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.